InvestorsHub Logo
Followers 1326
Posts 248768
Boards Moderated 64
Alias Born 12/07/2009

Re: None

Tuesday, 11/14/2023 9:32:12 AM

Tuesday, November 14, 2023 9:32:12 AM

Post# of 118383
$RGBP has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.

👉Currently in pre-clinical development

👉We expect that inhibition of this checkpoint protects CAR-T cells from exhaustion, a common problem of existing CAR-T cell therapies

👉Blocking NR2F6 in CAR-T cells should also make these cells more effective at killing solid tumors.
Bullish
Bullish

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!